↓ Skip to main content

Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-co…

Overview of attention for article published in Orphanet Journal of Rare Diseases, May 2019
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
24 Dimensions

Readers on

mendeley
135 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial
Published in
Orphanet Journal of Rare Diseases, May 2019
DOI 10.1186/s13023-019-1066-9
Pubmed ID
Authors

Sven Dittrich, Erika Graf, Regina Trollmann, Ulrich Neudorf, Ulrike Schara, Antje Heilmann, Maja von der Hagen, Brigitte Stiller, Janbernd Kirschner, Robert Dalla Pozza, Wolfgang Müller-Felber, Katja Weiss, Katja von Au, Markus Khalil, Reinald Motz, Christoph Korenke, Martina Lange, Ekkehard Wilichowski, Joseph Pattathu, Friedrich Ebinger, Nicola Wiechmann, Rolf Schröder

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 135 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 13%
Researcher 14 10%
Student > Master 14 10%
Student > Doctoral Student 13 10%
Other 10 7%
Other 27 20%
Unknown 40 30%
Readers by discipline Count As %
Medicine and Dentistry 36 27%
Nursing and Health Professions 13 10%
Pharmacology, Toxicology and Pharmaceutical Science 11 8%
Biochemistry, Genetics and Molecular Biology 10 7%
Agricultural and Biological Sciences 5 4%
Other 17 13%
Unknown 43 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2019.
All research outputs
#13,411,687
of 23,146,350 outputs
Outputs from Orphanet Journal of Rare Diseases
#1,368
of 2,651 outputs
Outputs of similar age
#170,536
of 350,442 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#30
of 59 outputs
Altmetric has tracked 23,146,350 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,651 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,442 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.